The true efficacy of medical therapy is well known, and it does not control hormonal excess in all patients with acromegaly: control rates of first-generation SRLs treatment were 56% for mean GH and 55% for IGF1 normalization [24]; the rate of biochemical control of acromegaly during Pasireotide ranged from 27% to 93% of cases [25]; finally, several studies have shown that Pegvisomant is efficient in normalizing IGF1 hypersecretion from 58% to 97% of patients [26]. The gene discussed is IGF1; the disease is acromegaly.